For instance, treatment of metastatic prostate cancer with sipuleucel-T, a cellular product based on enriched blood APCs briefly cultured with a fusion protein consisting of prostatic acid phosphatase linked to the DC growth and differentiation factor granulocyte macrophage colony-stimulating factor (GM-CSF), achieved an approximately 4-month improvement in median survival [18, 19]. The gene discussed is CSF2; the disease is metastatic prostate carcinoma.